PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Attorney Docket No. 006420,00004)

Dharmadhikari, et al. Application No. 10/526,285 Filing Date: March 2, 2005 For: PHARMACEUTICAL COMPOSITION OF METAXALONE WITH ENHANCED ORAL BIOAVAILABILITY BY Examiner: Michel Graffer Art Unit: 1614 Confirmation No. 4683	In re U.S. Patent Application of)
Application No. 10/526,285) Filing Date: March 2, 2005) For: PHARMACEUTICAL COMPOSITION OF) METAXALONE WITH ENHANCED ORAL) Art Unit: 1614 Confirmation No. 4683	Dharmadhikari, et al.)
Filing Date: March 2, 2005) For: Pharmaceutical Composition of) METAXALONE WITH ENHANCED ORAL)	Application No. 10/526,285) Examiner: Michel Graffeo)
) Confirmation No. 4683 For: Pharmaceutical Composition of) Metaxalone with Enhanced Oral)	Filing Date: March 2 2005) Art Unit: 1614
METAXALONE WITH ENHANCED ORAL)	,) Confirmation No. 4683
/)
Bioavailability)	METAXALONE WITH ENHANCED ORAL)
	Bioavailability)

AMENDMENT AND SUPPLEMENTAL RESPONSE

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

The final Office Action mailed June 16, 2006 and the Advisory Action mailed November 17, 2006 have been carefully reviewed and this communication was prepared in response thereto. Concurrently filed with this Amendment and Supplemental Response is a Request for Continued Examination (RCE), and a petition for a two month extension of time. The Advisory Action notes that the Response is due 4 months from the mailing date of the final Office Action. This Amendment and Supplemental Response is intended to replace the Amendment filed October 13, 2006, which was not entered as noted in the Advisory Action. The Office is authorized to charge the extension fee, minus the one month extension fee already paid, to Deposit Account No. 19-0733. If any other fee is due, the Office is authorized to charge such a fee to Deposit Account No. 19-0733.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the Listing of Claims, which begins on page 3 of this paper.

Remarks/Arguments begin on page 6 of this paper.